Latest News

The FDA approved oveporexton for narcolepsy type 1 in adults, marking the first orexin receptor agonist targeting the underlying biological cause of narcolepsy.

Community health workers and population health screening tactics help primary care teams address SDOH and reduce hospital utilization.

The FDA has approved mFLUSIVA, Moderna's first mRNA flu vaccine, for adults 50 and older ahead of the 2026-2027 season.

FDA approved Mucinex 12HR Cold & Fever Multi-Symptom, an OTC product combining guaifenesin, dextromethorphan, and naproxen sodium.

FDA approval of centanafadine could expand ADHD treatment for patients aged 6 years or older, but labeling and pivotal data remain unavailable.

A McGill University–led team developed a prediction model integrating pregnancy-related factors to identify cardiovascular disease risk in women aged 15 to 45.

Recent FDA actions include approvals and clearances in lipid management, CRC screening, contraception, vaginitis testing, and Alzheimer psychosis.

Shpiner examines why physician trust has declined for years and how AI use reflects, not causes, that shift.